Rajko Reljic, EMI-TB PI at St. George's University of London, is participating in the Vaccine development for complex Intracellular neglected pathogens (VALIDATE) network for vaccine R&D, funded jointly by the UK MRC and BBSRC. The VALIDATE network provides a forum for cross-disciplinary and cross-organism research and directly funds projects aimed at delivering at better understanding of protective immune responses in both animal and human diseases caused by intracellular pathogens. EMI-TB scientist Alastair Copland has recently been awarded a VALIDATE project grant to study the role of alveolar macrophages induced by mucosal immunisation in collaboration with Prof Tracy Hussell at the University of Mancester.


Co-ordination /


Scientific Steering


(WP Leads)




Dr Rajko Reljic

Scientific Co-ordinator

Dr Rajko Reljic







Dr Rajko Reljic








Dr Barry Walker

AERAS Foundation

Project Manager

Dr Mathew Paul








Dr Sally Sharpe








Prof. Kris Huygen

Scientific Institute

for Public Health, Belgium

Dr Harry ThangarajProject IP Manager

Dr Harry Thangaraj







Prof. África 









Prof. Francesco Dieli 









Prof. Mahavir Singh 








Dr Tufária Mussá




EMI-TB Geographical Map

InstitutionNameRole in EMI-TB

St George's, University of London, UK

PI: Dr Rajko Reljic

Comparative testing of mucosal vaccine candidates, immune response analysis, coordination and management

King's College London, UK

PI: Prof. Juraj Ivanyi

Testing of peptide epitopes

Karolinska Institutet, Sweden

PI: Prof. Martin Rottenberg

Testing of vaccine candidates, correlates of protection

Universidade De Vigo, Spain

PI: Prof. Africa Gonzalez-Fernandez

Provision and immunological analysis of clinical samples, correlates of protection


CEO: Prof. Mahavir Singh

Provision of recombinant fusion proteins

Azienda Ospedialiera Universitaria

Policlinico Paolo Giaccone Palermo, Italy

PI: Prof. Francesco Dieli

Identification of novel T-cell epitopes

Sporegen Ltd.

CEO: Prof. Simon Cutting

Provision and optimisation of Bacillus subtilis spores

Stockholms Universitat, Sweden

PI: Prof. Carmen Fernandez

Innate immune correlates of protection

CSIC, Spain

PI: Dr. Mónica Carrera

Proteomic analysis of clinical samples

Universita degli Studi di Roma

Tor Vergana, Italy

PI: Prof. Maurizio Fraziano

Provision of liposomes for the delivery of T-cell epitopes

IGTP, Spain  

PI: Prof. Pere-Joan Cardona                                            

Testing of vaccine candidates             

Public Health England, UK

PI: Dr Sally Sharpe

Testing of vaccine candidates

Instituto Nacionale do Saude, Mozambique

PI: Dr Tufaria Mussa

Provision of clinical samples

IMIC, Czech Republic

PI: Prof. Peter Sebo

Provision of vaccine delivery systems


TB Facts:

  • In 2013, 9 million people were diagnosed with TB and 1.5 million died from it
  • TB is the second largest killer among infectious diseases (after HIV)
  • TB is a common secondary infection in HIV+ individuals, and one of the major causes of death in AIDS
  • In 2013, 360,000 AIDS sufferers died from TB
  • TB is caused by the bacterium Mycobacterium tuberculosis
  • About one third of the world's population carries the TB pathogen in a dormant form
  • TB is diagnosed by chest X-ray, microbiological analysis of sputum and immunological tests
  • The standard treatment for TB involves 6 months of antimicrobial therapy with 4 drugs
  • Multi-drug resistant TB (MDR-TB) can arise due to incomplete treatment
  • In 2013, 450,000 people were diagnosed with MDR-TB
  • BCG is the only available vaccine against TB, but it is not always effective


                                             Source: WHO TB Report 2013



Further Information about TB:

WHO TB Fact Sheet

Stop TB Partnership


NHS - TB Information

TB Vaccine Initiative


EMI-TB is an EU Horizon2020 funded action focused on selecting and developing a novel vaccine candidate for TB.


EMI-TB motifTuberculosis (TB) is a global health problem, killing 1.5 million people every year. The only currently available vaccine, Mycobacterium bovis BCG, is effective against severe childhood forms, but it demonstrates variable efficacy against the pulmonary form of TB in adults. Many of these adult TB cases result from the reactivation of an initially controlled, latent Mycobacterium tuberculosis (MTB) infection. Effective prophylactic vaccination remains the key long-term strategy for combating TB Continued belief in reaching this goal requires unrelenting innovation in the formulation and delivery of candidate vaccines.


EMI-TB aims to: 


  • Establish an optimal vaccine delivery system for inducing protective mucosal immunity against MTB.
  • Identify novel, early stage infection associated CD8+ T-cell epitopes for inducing protective cell mediated immunity.
  • To establish correlates of a protective immune response in MTB-exposed humans and vaccinated animals.
  • To extensively test the most promising vaccine candidate in preparation for future clinical trials.



12 research groups are participating in the EMI-TB action, including a partner from Mozambique. Our research is supported by 2 SME partners. Click here to learn more about the groups involved in EMI-TB.